As interferon/ribavirin-based standard therapy is curative in only about half of HCV patients,
there remains an important need for alternatives including vaccines. The novel peptide …

Background & Aims: IC41 is a synthetic peptide vaccine containing 7 relevant hepatitis C
virus (HCV) T-cell epitopes and the T helper cell (Th) 1/Tc1 adjuvant poly-L-arginine. IC41 …

BACKGROUND: An effective vaccine would be a significant progress in the management of
chronic HCV infections. This study was designed to examine whether different application …

To assess the safety and immune responses to a personalized peptide vaccination of
hepatitis C virus (HCV) 1b-derived peptides, 12 HCV1b-positive patients, who were …

Hepatitis C virus (HCV) is a widespread infectious disease in humans with the negative
implication of becoming chronic in most persons. Patients infected with HCV are at risk of …

Hepatitis C virus (HCV) infects more than 170 million people globally and is a leading cause
of liver cirrhosis, transplantation and hepatocellular carcinoma. Current gold-standard …

Hepatitis C virus (HCV) infection has a high risk of liver cirrhosis and hepatocellular
carcinoma at later stages. We recently identified a peptide derived from the HCV core …

We examined the effect of the hepatitis C virus (HCV) peptide vaccine IC41 on HCV-specific
T-cell responses and virological relapse rates in patients with chronic HCV genotype 1 …

Hepatitis C virus (HCV) is a blood borne disease estimated to chronically infect 3% of the
worlds' population causing significant morbidity and mortality. Current medical therapy is …

The hepatitis C virus (HCV), first described in 1989, is now a leading cause of liver cirrhosis
and hepatocellular carcinoma. With more than 170 million people infected globally, this virus …